Protagonist Therapeutics, Inc.

NASDAQ:PTGX

Biotechnology

Healthcare
$127.16 +1.54%

+$1.72 today

Market cap
$8.30B
Beta
1.83
P/E (TTM)
-64.2
EPS (TTM)
-$1.76
52W Low $49.38High $114.00

Volume 0.43M

Average 0.72M

PTGX Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Protagonist Therapeutics, Inc.NASDAQ: PTGX

Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026

Cash & equivalents rises 149.2% from a year ago

Cash & equivalents stood at $420.08M at the end of Q2 FY2026, up 149.2% from a year earlier and up 116.9% from the prior quarter. Over 3 fiscal years it compounded at +0.7% a year.

Context

  • Cash & equivalents amounted to 47.4% of total assets at the end of Q2 FY2026, up 24.0 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +149.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$420.08M+116.9% QoQ
Last fiscal yearDec 2025
$128.39M+32.0% YoY
Year agoJun 2025
$168.54M+149.2% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+149.2%——
1 year+32.0%——
3-year CAGR+0.7%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
128.39M USD
Year-over-year change
+32.0%
4-year CAGR
+0.9%

Cash & Equivalents vs competitors

How PTGX compares with its peers on the latest reported figures

  • PTGX's Jun 2026 cash & equivalents of $420.08M is the 2nd highest of the 7 companies compared; the peer median is $138.31M.
  • Its year-over-year change of +149.2% is the 3rd highest of 7, against a peer median of +32.9%.
  • Cash & equivalents amounts to 47.4% of total assets for PTGX, versus a peer median of 44.9%.
PTGX Competitors Peer median
Cash & Equivalents for PTGX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IMVTImmunovant, Inc.Sep 2026$722.27M +38.4%+33.8%94.9%
PTGXProtagonist Therapeutics, Inc.Jun 2026$420.08M +149.2%+0.7%47.4%
ANABAnaptysBio, Inc.Mar 2026$248.47M +151.9%+49.5%75.4%
IMUXImmunic, Inc.Mar 2026$186.63M +1204.7%-47.5%98.4%
IRONDisc Medicine, Inc.Sep 2026$89.98M -36.0%-22.3%12.9%
SYRESpyre Therapeutics, Inc.Sep 2026$82.73M +27.5%+35.0%7.5%
ACRSAclaris Therapeutics, Inc.Mar 2026$28.66M -5.6%-23.9%14.4%
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding PTGX) $138.31M+32.9%+5.7%44.9%

Competitors are the stored peer set for PTGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents123.67M125.74M186.73M97.25M128.39M
Short-term Investments203.24M111.61M154.89M321.66M438.97M
Net Receivables5.33M52K10.33M168.49M4.5M
Inventory00000
Other Current Assets00000
Total Current Assets340.74M243.08M355.58M591.64M577.57M
Property, Plant & Equipment (Net)6.73M4.63M2.15M12.61M11.69M
Goodwill00000
Intangible Assets00000
Long-term Investments000140.25M78.93M
Tax Assets00001.71M
Other Non-current Assets225K225K225K225K0
Total Non-current Assets6.96M4.85M2.37M153.08M92.32M
Total Assets347.7M247.93M357.95M744.73M669.89M
Account Payables1.6M3.64M772K1.62M5.34M
Short-term Debt000510K2.28M
Tax Payables0002.69M0
Deferred Revenue2.5M69K018.89M9.55M
Other Current Liabilities7.13M4.97M6.79M12.62M15.51M
Total Current Liabilities44.02M31.18M21.27M47.4M45.44M
Long-term Debt00000
Deferred Tax Liabilities00221K01.71M
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00(221K)11.68M0
Total Non-current Liabilities3.66M1.14M022.03M9.74M
Total Liabilities47.67M32.32M21.27M69.43M55.19M
Common Stock001K1K1K
Retained Earnings(409.36M)(536.76M)(615.71M)(340.52M)(470.67M)
Accumulated OCI(299K)(359K)(105K)(82K)641K
Other Stockholders Equity00000
Minority Interest00000
Total Equity300.02M215.61M336.68M675.3M614.71M
Total Debt5.86M3.66M1.14M10.87M10.32M
Net Debt(117.81M)(122.09M)(185.59M)(86.38M)(118.07M)

Protagonist Therapeutics, Inc.

NASDAQ:PTGX

Intrinsic Alpha fair value

Locked

Current Price

$127.16

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.